Trial Profile
The combined therapy with Olmesartan and Azelnidipin in the hypertensive patients with sleep apnea syndrome (SAS)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary) ; Amlodipine
- Indications Hypertension; Sleep apnoea syndrome
- Focus Therapeutic Use
- 13 Feb 2018 Status changed from not yet recruiting to discontinued.
- 07 Feb 2012 New trial record